Quantitative strength testing in ALS clinical trials

Neurology

Volumn 87, Issue 6, 2016, Pages 617-624

  Shefner, Jeremy M ^a   Liu, Dawei ^b   Leitner, Melanie L ^b   Schoenfeld, David ^c   Johns, Donald R ^b   Ferguson, Toby ^b   Cudkowicz, Merit ^c  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

^b BIOGEN   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; DEXPRAMIPEXOLE; PLACEBO; RILUZOLE; BENZOTHIAZOLE DERIVATIVE; PRAMIPEXOLE;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; AMYOTROPHIC LATERAL SCLEROSIS FUNCTIONAL RATING SCALE; ANKLE; ARTICLE; CORRELATION COEFFICIENT; DOUBLE BLIND PROCEDURE; DYNAMOMETRY; ELBOW; FOLLOW UP; HAND HELD DYNAMOMETRY; HIP; HUMAN; KNEE; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); MUSCLE STRENGTH; NEUROLOGIC DISEASE ASSESSMENT; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHOULDER; VITAL CAPACITY; WRIST; CLINICAL TRIAL; CONTROLLED STUDY; DYNAMOMETER; FEMALE; MALE; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

AMYOTROPHIC LATERAL SCLEROSIS; BENZOTHIAZOLES; CEFTRIAXONE; FEMALE; HUMANS; MALE; MUSCLE STRENGTH DYNAMOMETER; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 84981165468     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000002941     Document Type: Article

References (16)

1. Miller RG, Block G, Katz JS, et al. Randomized phase 2 trial of NP001-A novel immune regulator: safety and early efficacy in ALS. Neurol Neuroimmunol Neuroinflamm 2015; 2: e100
2. Lenglet T, Lacomblez L, Abitbol JL, et al. A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis. Eur J Neurol 2014; 21: 529-536
3. Cudkowicz ME, van den Berg LH, Shefner JM, et al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, doubleblind, phase 3 trial. Lancet Neurol 2013; 12: 1059-1067
4. Aggarwal SP, Zinman L, Simpson E, et al. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010; 9: 481-488
5. Robbins RA, Simmons Z, Bremer BA, Walsh SM, Fischer S. Quality of life in ALS is maintained as physical function declines. Neurology 2001; 56: 442-444
6. Traynor B, Zhang H, Shefner J, Schoenfeld D, Cudkowicz M. Functional outcome measures as clinical trial endpoints in amyotrophic lateral sclerosis. Neurology 2004; 63: 1933-1935
7. Czaplinski A, Yen AA, Appel SH. Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. J Neurol Neurosurg Psychiatry 2006; 77: 390-392
8. Czaplinski A, Yen AA, Simpson EP, Appel SH. Predictability of disease progression in amyotrophic lateral sclerosis. Muscle Nerve 2006; 34: 702-708
9. Great Lakes ALS Study Group. A comparison of muscle strength testing techniques in amyotrophic lateral sclerosis. Neurology 2003; 61: 1503-1506
10. Meininger V, Drory VE, Leigh PN, Ludolph A, Robberecht W, Silani V. Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a doubleblind, randomized, multicentre, placebo-controlled trial. Amyotroph Lateral Scler 2009; 10: 378-383
11. Meininger V, Bensimon G, Bradley WR, et al. Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5: 107-117
12. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis: ALS/Riluzole Study Group. N Engl J Med 1994; 330: 585-591
13. Andres PL, Thibodeau LM, Finison LJ, Munsat TL. Quantitative assessment of neuromuscular deficit in ALS. Neurol Clin 1987; 5: 125-141
14. Cudkowicz ME, Titus S, Kearney M, et al. Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multistage, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2014; 13: 1083-1091
15. Rutkove SB, Caress JB, Cartwright MS, et al. Electrical impedance myography as a biomarker to assess ALS progression. Amyotroph Lateral Scler 2012; 13: 439-445
16. Shefner JM, Watson ML, Simionescu L, et al. Multipoint incremental motor unit number estimation as an outcome measure in ALS. Neurology 2011; 77: 235-241